ADRMF (Adherium) 3-Year ROIIC % : -21.78% (As of Jun. 2025)


What is Adherium 3-Year ROIIC %?

Adherium ADRMF 3-Year ROIIC % is -21.78 as of Jun. 2025. The stock has 8 warning signs investors should review. Among 801 Medical Devices & Instruments companies, Adherium ranks worse than 69.54% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Adherium's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was -21.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Adherium's 3-Year ROIIC % or its related term are showing as below:

ADRMF's 3-Year ROIIC % is ranked worse than
69.54% of 801 companies
in the Medical Devices & Instruments industry
Industry Median: 1.12 vs ADRMF: -21.78

Adherium  (OTCPK:ADRMF) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Adherium 3-Year ROIIC % Related Terms


Adherium 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Adherium's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adherium 3-Year ROIIC % Chart

Adherium Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -761.50 -27.13 -323.21 -229.12 -21.78

Adherium Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -229.12 0.00 -21.78 0.00

ADRMF vs ABT, SYK, MDT: 3-Year ROIIC % Comparison

For the Medical Devices subindustry, Adherium's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adherium 3-Year ROIIC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Adherium's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Adherium's 3-Year ROIIC % falls into.



Adherium 3-Year ROIIC % Calculation

Adherium's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -9.027 (Jun. 2025) - -9.176 (Jun. 2022) )/( 3.436 (Jun. 2025) - 1.102 (Jun. 2022) )
=0.149/2.334
=6.38%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of -21.78 mean?
Adherium (ADRMF) has a 3-Year ROIIC % of -21.78 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Adherium and its competitors. According to the industry distribution chart, Adherium ranks #557 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 69.5%.
Is Adherium's 3-Year ROIIC % too high?
Adherium's current 3-Year ROIIC % is -21.78. Based on the distribution chart, Adherium ranks #557 out of 801 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Adherium's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Adherium ranks #557 out of 801 companies for 3-Year ROIIC %. This places Adherium in the lower half of its industry. The industry median 3-Year ROIIC % is 1.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.12, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Adherium and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adherium's current 3-Year ROIIC % is -21.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Based on GuruFocus' analysis, Adherium (ADRMF) is currently considered Possible Value Trap. The current 3-Year ROIIC % is -21.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Adherium (ADRMF), the current 3-Year ROIIC % is -21.78 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adherium Business Description

Other Exchanges ADR:Australia
Address 447 Collins Street, Level 5, Melbourne, VIC, AUS, 3000
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.